By Donnie Yance
“Conformity is the jailer of freedom and the enemy of growth.” – John F. Kennedy, 35th U.S. president
It’s the new year again and weight loss goals are on the minds of millions of people in America and around the world.
Before you dive into this blog you may want to review several of my previous blogs including (August 3, 2023), “Are Diabetic Weight Loss Drugs Really The New Diet? Discover the Benefits Of Intuitive Eating.”
GLP−1 Receptor Agonists For the Treatment of Obesity
Glucagon-like peptide-1 receptor (GLP-1R) agonists represent a groundbreaking class of medications that target incretin hormone pathways. Incretins stimulate the pancreas to release insulin, which helps regulate blood sugar. They also regulate how much sugar is released from the liver and slow down digestion.
Extensive preclinical studies and robust clinical trials have demonstrated the efficacy of GLP-1R agonists in both treating and preventing obesity. By mimicking the effects of our own GLP-1, these agents not only promote a feeling of fullness and reduce food intake but also enhance glucose balance. Given their multifaceted therapeutic benefits and favorable safety profile, GLP-1R agonists have emerged as particularly promising options for individuals struggling with obesity, offering a potential paradigm shift in medical weight management.1
Continue reading “Weight Loss Injections? Semaglutide and Liraglutide: The Good, the Bad, and the Ugly -Part 1”